Alpha-synuclein research: defining strategic moves in the battle against Parkinson’s disease
<div><p>With the advent of the genetic era in Parkinson’s disease (PD) research in 1997, α-synuclein was identified as an important player in a complex neurodegenerative disease that affects >10 million people worldwide. PD has been estimated to have an economic impact of $51.9 billio...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , , , , , , , , , , , , , , , , , , |
| Published: |
2021
|
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1864513517758971904 |
|---|---|
| author | Luis M. A. Oliveira (18459000) |
| author2 | Thomas Gasser (33499) Robert Edwards (1230) Markus Zweckstetter (133481) Ronald Melki (102380) Leonidas Stefanis (264252) Hilal A. Lashuel (261037) David Sulzer (86849) Kostas Vekrellis (214282) Glenda M. Halliday (11232982) Julianna J. Tomlinson (15257035) Michael Schlossmacher (4377472) Poul Henning Jensen (7490708) Julia Schulze-Hentrich (18459003) Olaf Riess (110686) Warren D. Hirst (238891) Omar El-Agnaf (2134222) Brit Mollenhauer (482499) Peter Lansbury (5154518) Tiago F. Outeiro (191379) |
| author2_role | author author author author author author author author author author author author author author author author author author author |
| author_facet | Luis M. A. Oliveira (18459000) Thomas Gasser (33499) Robert Edwards (1230) Markus Zweckstetter (133481) Ronald Melki (102380) Leonidas Stefanis (264252) Hilal A. Lashuel (261037) David Sulzer (86849) Kostas Vekrellis (214282) Glenda M. Halliday (11232982) Julianna J. Tomlinson (15257035) Michael Schlossmacher (4377472) Poul Henning Jensen (7490708) Julia Schulze-Hentrich (18459003) Olaf Riess (110686) Warren D. Hirst (238891) Omar El-Agnaf (2134222) Brit Mollenhauer (482499) Peter Lansbury (5154518) Tiago F. Outeiro (191379) |
| author_role | author |
| dc.creator.none.fl_str_mv | Luis M. A. Oliveira (18459000) Thomas Gasser (33499) Robert Edwards (1230) Markus Zweckstetter (133481) Ronald Melki (102380) Leonidas Stefanis (264252) Hilal A. Lashuel (261037) David Sulzer (86849) Kostas Vekrellis (214282) Glenda M. Halliday (11232982) Julianna J. Tomlinson (15257035) Michael Schlossmacher (4377472) Poul Henning Jensen (7490708) Julia Schulze-Hentrich (18459003) Olaf Riess (110686) Warren D. Hirst (238891) Omar El-Agnaf (2134222) Brit Mollenhauer (482499) Peter Lansbury (5154518) Tiago F. Outeiro (191379) |
| dc.date.none.fl_str_mv | 2021-07-26T03:00:00Z |
| dc.identifier.none.fl_str_mv | 10.1038/s41531-021-00203-9 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/Alpha-synuclein_research_defining_strategic_moves_in_the_battle_against_Parkinson_s_disease/25712283 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Neurosciences Parkinson’s disease (PD) α-synuclein Genetic era Neurodegenerative disease Epidemiology Economic impact Research Functions |
| dc.title.none.fl_str_mv | Alpha-synuclein research: defining strategic moves in the battle against Parkinson’s disease |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <div><p>With the advent of the genetic era in Parkinson’s disease (PD) research in 1997, α-synuclein was identified as an important player in a complex neurodegenerative disease that affects >10 million people worldwide. PD has been estimated to have an economic impact of $51.9 billion in the US alone. Since the initial association with PD, hundreds of researchers have contributed to elucidating the functions of α-synuclein in normal and pathological states, and these remain critical areas for continued research. With this position paper the authors strive to achieve two goals: first, to succinctly summarize the critical features that define α-synuclein’s varied roles, as they are known today; and second, to identify the most pressing knowledge gaps and delineate a multipronged strategy for future research with the goal of enabling therapies to stop or slow disease progression in PD.</p><p> </p></div><h2>Other Information</h2> <p> Published in: npj Parkinson's Disease<br> License: <a href="https://creativecommons.org/licenses/by/4.0" target="_blank">https://creativecommons.org/licenses/by/4.0</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1038/s41531-021-00203-9" target="_blank">https://dx.doi.org/10.1038/s41531-021-00203-9</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_4d7ce29af607b660ff9e628ee5d154fa |
| identifier_str_mv | 10.1038/s41531-021-00203-9 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/25712283 |
| publishDate | 2021 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Alpha-synuclein research: defining strategic moves in the battle against Parkinson’s diseaseLuis M. A. Oliveira (18459000)Thomas Gasser (33499)Robert Edwards (1230)Markus Zweckstetter (133481)Ronald Melki (102380)Leonidas Stefanis (264252)Hilal A. Lashuel (261037)David Sulzer (86849)Kostas Vekrellis (214282)Glenda M. Halliday (11232982)Julianna J. Tomlinson (15257035)Michael Schlossmacher (4377472)Poul Henning Jensen (7490708)Julia Schulze-Hentrich (18459003)Olaf Riess (110686)Warren D. Hirst (238891)Omar El-Agnaf (2134222)Brit Mollenhauer (482499)Peter Lansbury (5154518)Tiago F. Outeiro (191379)Biomedical and clinical sciencesNeurosciencesParkinson’s disease (PD)α-synucleinGenetic eraNeurodegenerative diseaseEpidemiologyEconomic impactResearchFunctions<div><p>With the advent of the genetic era in Parkinson’s disease (PD) research in 1997, α-synuclein was identified as an important player in a complex neurodegenerative disease that affects >10 million people worldwide. PD has been estimated to have an economic impact of $51.9 billion in the US alone. Since the initial association with PD, hundreds of researchers have contributed to elucidating the functions of α-synuclein in normal and pathological states, and these remain critical areas for continued research. With this position paper the authors strive to achieve two goals: first, to succinctly summarize the critical features that define α-synuclein’s varied roles, as they are known today; and second, to identify the most pressing knowledge gaps and delineate a multipronged strategy for future research with the goal of enabling therapies to stop or slow disease progression in PD.</p><p> </p></div><h2>Other Information</h2> <p> Published in: npj Parkinson's Disease<br> License: <a href="https://creativecommons.org/licenses/by/4.0" target="_blank">https://creativecommons.org/licenses/by/4.0</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1038/s41531-021-00203-9" target="_blank">https://dx.doi.org/10.1038/s41531-021-00203-9</a></p>2021-07-26T03:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1038/s41531-021-00203-9https://figshare.com/articles/journal_contribution/Alpha-synuclein_research_defining_strategic_moves_in_the_battle_against_Parkinson_s_disease/25712283CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/257122832021-07-26T03:00:00Z |
| spellingShingle | Alpha-synuclein research: defining strategic moves in the battle against Parkinson’s disease Luis M. A. Oliveira (18459000) Biomedical and clinical sciences Neurosciences Parkinson’s disease (PD) α-synuclein Genetic era Neurodegenerative disease Epidemiology Economic impact Research Functions |
| status_str | publishedVersion |
| title | Alpha-synuclein research: defining strategic moves in the battle against Parkinson’s disease |
| title_full | Alpha-synuclein research: defining strategic moves in the battle against Parkinson’s disease |
| title_fullStr | Alpha-synuclein research: defining strategic moves in the battle against Parkinson’s disease |
| title_full_unstemmed | Alpha-synuclein research: defining strategic moves in the battle against Parkinson’s disease |
| title_short | Alpha-synuclein research: defining strategic moves in the battle against Parkinson’s disease |
| title_sort | Alpha-synuclein research: defining strategic moves in the battle against Parkinson’s disease |
| topic | Biomedical and clinical sciences Neurosciences Parkinson’s disease (PD) α-synuclein Genetic era Neurodegenerative disease Epidemiology Economic impact Research Functions |